Protagonist Therapeutics, Inc.NASDAQ: PTGX

Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting

· Issued by Protagonist Therapeutics, Inc.
Watch Protagonist Therapeutics explain itProtagonist Therapeutics, Inc. (PTGX) Q4 2020 Earnings Call · Replay · Mar 10, 2021

54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (5/year:

  • In Part 1, the EPHL was